# Viral Clearance, PK and Tolerability of Ensovibep in COVID-19 Patients

> **NCT04834856** · PHASE2 · COMPLETED · sponsor: **Molecular Partners AG** · enrollment: 12 (actual)

## Conditions studied

- Covid19

## Interventions

- **DRUG:** ensovibep

## Key facts

- **NCT ID:** NCT04834856
- **Lead sponsor:** Molecular Partners AG
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-04-01
- **Primary completion:** 2021-08-20
- **Final completion:** 2021-08-20
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2021-09-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04834856

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04834856, "Viral Clearance, PK and Tolerability of Ensovibep in COVID-19 Patients". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04834856. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*